The NIDA Avant-Garde Award Program for HIV/AIDS Research supports exceptionally creative scientists, who propose high-impact research that will open new areas of HIV/AIDS research in the context of Substance Use Disorders (SUD) and/or lead to new avenues for prevention and treatment of HIV/AIDS in people who use drugs (PWUD). The term “avant-garde” refers to highly innovative ideas and/or approaches that have the potential to be transformative.
Deadline: August 13, 2020
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells.
Deadline: October 2, 2020
The intent of the FY20 PRARP ADTBI is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for chronic TBI as they pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice.
Deadline: July 21, 2020
The Discovery Research PreK-12 program (DRK-12) seeks to significantly enhance the learning and teaching of science, technology, engineering, mathematics and computer science (STEM) by preK-12 students and teachers, through research and development of STEM education innovations and approaches. Projects in the DRK-12 program build on fundamental research in STEM education and prior research and development efforts that provide theoretical and empirical justification for proposed projects. Projects should result in research-informed and field-tested outcomes and products that inform teaching and learning. Teachers and students who participate in DRK-12 studies are expected to enhance their understanding and use of STEM content, practices and skills.
Deadline: October 7, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to establish a Coordinating Unit to support the Kidney, Urology and Hematology (KUH) Innovative Science Accelerator (ISAC-CU) Program. The ISAC-CU will administer a collaborative funding program intended to seed high-impact science of interest to the KUH research community.
Deadline: August 4, 2020
This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single-site clinical trials that: (1) address barriers that impede population-level implementation of case finding and cascade screening (i.e., blood relatives of FH index cases are systematically contacted based on their risk according to the pattern of inheritance); (2) explore implementation science methodologies to assess the uptake, cost-effectiveness, feasibility, and scalability of family-based cascade screening programs for familial hypercholesterolemia (FH); (3) develop or improve machine learning algorithms and data mining techniques to find high-risk individuals using electronic health records (EHRs); and (4) optimize treatment strategies and health outcomes.
Deadline: March 8, 2021
The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA seeks applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration cancer registry data and to expand the data items collected. Applications must be built on partnership with U.S. population-based central cancer registries (a partnership must involve at least two different registries). Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.
Deadline: November 18, 2020
The opening of this PCORI Funding Announcement has been moved back to June 9, 2020.
This PCORI funding announcement invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs. The proposed trials should address important decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions. Proposed studies should compare interventions that already have established evidence of efficacy or are in widespread use. Clinical interventions (such as medications, diagnostic tests, or procedures) and delivery system interventions are appropriate for study.
- LOI: September 29, 2020
- Full Application: January 12, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
Please read the full program announcement before preparing your internal application.
- Application budgets are limited to $900,000 in direct costs per year, excluding the IOF budget, and need to reflect the actual needs of the proposed project.
- The maximum project period is 5 years.
- Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for Note that the multiple PD(s)/PI(s) option may be used only for the Overall Program. Projects are limited to a single project lead per project and a single core lead per core within the multi-component application.
- An investigator can serve as a PD/PI on only one AADCRC award or application. This includes all PD(s)/PI(s) of a multiple-PD/PI application
- NIH support.
- Detailed application review criteria can be found here.
An Institution may submit one proposal.
If you are interested in submitting for this program, you must first submit an internal application to firstname.lastname@example.org to the required instructions below.
Internal Applications must include the following:
- A cover page listing
- The name of this funding opportunity and title of your proposal
- Your name, UGA position, home department, email, and UGA contact information
- Collaborator names, positions, and institutions (if any)
- Indicate whether or not you have submitted to this program in the past. If so, please provide a copy of the review at the end of the internal application.
- A (maximum two-page) proposal summary that addresses the program’s specific selection criteria.
- One paragraph describing why this proposal should be UGA’s submission (i.e., why it will be the most competitive for this program)
- A two-page Curriculum vitae
Limited Submission announcements often generate multiple competing proposals. UGA reviewers judge proposals as they would in any peer review process, so PIs are urged to put their best foot forward. Along with typical criteria, reviewers will evaluate internal proposals based on their fit with the sponsor’s articulated goals and criteria.
Internal Submission Instructions
The above internal application materials should be submitted via email as a single .PDF file to email@example.com by the internal deadline listed above.
Please submit questions regarding the internal competition to firstname.lastname@example.org.
For questions directly related to this program, please contact the following program officers:
Gang Dong, MD, PhD
View our calendar for all Current and Closed Limited Submissions.
Subscribe to our listerv to receive weekly internal competition announcements.
What is a Limited Submission?
This FOA encourages applications to advance the discovery, preclinical development, and proof of concept testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders or alcohol use disorders, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.
Deadline: July 27, 2020